<DOC>
	<DOCNO>NCT00795548</DOCNO>
	<brief_summary>This open label phase-II trial evaluate hematological response additional treatment 5-Azacitidine common DLI patient MDS AML relapse allogeneic stem cell transplantation .</brief_summary>
	<brief_title>Safety Study 5-Azacitidine Standard Donor Lymphocyte Infusion ( DLI ) Treat Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS ) Relapsing After Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Relapse allogeneic stem cell transplantation major problem patient poor prognosis AML MDS . Donor lymphocyte infusion alone re-induce remission minority patient , may result poor differentiation leukemic cell . The study drug 5-Aza effective AML MDS.In addition direct cytotoxicity , alters gene expression induces differentiation leukemic blast cell . Furthermore , DNA-demethylating treatment result induction transcription cell surface expression formerly unexpressed KIRs ( killer Ig-like receptor ) NK cell , involve specific recognition leukemic target cell able generate specific graft-versus leukemia effect . The increased expression MHC class I II molecule surface recipient 's leukemic cell de novo expression formerly silence KIR gene donor NK cell due treatment 5-Aza may result increased susceptibility myeloid leukemic cell allogeneic graft versus leukemia effect . Therefore , graft-versus leukemia effect donor lymphocyte infusion NK cell original donor may support additional therapy 5-Azacitidine .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Primary secondary MDS , AML MDS , de novo AML relapse allogeneic stem cell transplantation Eligibility Donor Lymphocyte Infusions Performance status accord WHO scale : 0 , 1 2 . Adequate renal liver function : bilirubin &lt; 1.5 time upper limit normal GFR &gt; 50 ml/min Absence severe cardiovascular disease , i.e. , arrhythmia require chronic treatment , congestive heart failure ( NYHA Class III IV ) symptomatic ischemic heart disease , NewYork Heart Association ( NYHA ) HIV negative HBsAg negative . Absence active uncontrolled infection ( Septicaemia ) . No prior history current evidence central nervous system psychiatric disorder require hospitalization . Age least 18 year . Negative pregnancy test woman reproductive potential . Signed write informed consent must give accord national/local regulation . Have malignant hepatic tumor . Severe liver dysfunction CHILD B C. Renal insufficiency GFR &lt; 50 ml/min Radiation therapy , chemotherapy , cytotoxic therapy , give treat condition MDS , AML apply condition prior allogeneic stemcell transplantation . Psychiatric illness would prevent grant informed consent . Treatment androgenic hormone previous 14 day prior Day 1 . Active viral infection know human immunodeficiency virus ( HIV ) viral Hepatitis B C. Hypersensitivity Mannitol 5Azacitidine . Treatment investigational drug follow relapse allogeneic stemcell transplantation ongoing adverse event previous treatment investigational drug regardless time period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Myelodysplastic syndrome ( MDS )</keyword>
	<keyword>Acute myeloid leukemia ( AML )</keyword>
	<keyword>Stem cell transplantation</keyword>
	<keyword>5-Azacitidine</keyword>
	<keyword>Donor lymphocyte infusion</keyword>
	<keyword>MDS AML relapse stem cell transplantation</keyword>
</DOC>